Compositions and methods for inhibits the binding of GTP to oncogenic mutant KRas are disclosed. These compositions may be used in method to treat a subject with cancer. In particular, the compositions may be used to treat cancers involving overactive Ras signaling.

Compositions and methods for inhibits the binding of GTP to oncogenic mutant KRas are disclosed. These compositions may be used in method to treat a subject with cancer. In particular, the compositions may be used to treat cancers involving overactive Ras signaling.

A small molecule inhibitor of PD-1/PD-L1, a pharmaceutical composition thereof with a PD-L1 antibody, and an application of the same. The small molecule inhibitor of PD-1/PD-L1 is aromatic ethylene or aromatic ethylene derivative represented by general formula (I) and can be used to treat cancer.

##STR00001##

The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

The present invention relates to the field of anti-cancer compounds. More particularly, the invention relates to a family of benzothiazolyl urea or thiorurea compound useful as such agents. The present invention also relates to methods for treating cancers using these compounds.

Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent in the form of DMSO or DMI and at least one plant oil. The base solution was found to be highly versatile and provide superior or at least comparable skin penetration efficacy and active agent compatibility. Methods of treatment, uses of the solvent system and methods of manufacture are also described.

Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent in the form of DMSO or DMI and at least one plant oil. The base solution was found to be highly versatile and provide superior or at least comparable skin penetration efficacy and active agent compatibility. Methods of treatment, uses of the solvent system and methods of manufacture are also described.

A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM~1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM~1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.